

Study	Country	Effect size (95% CI)
<b>Panel A: MDA trials (prevalence &lt;20%)</b>		
Ndibazza 2012	Uganda	-0.07 [-0.26, 0.12]
Awasthi 2000	India	0.00 [-0.08, 0.08]
MDA trials (prevalence <20%)		-0.01 [-0.08, 0.06]
P-value = 0.773		
<b>Panel B: MDA trials (prevalence &gt;20%)</b>		
Le Huong 2007a	Vietnam	-0.08 [-0.35, 0.19]
Liu 2017	China	-0.04 [-0.25, 0.17]
Le Huong 2007b	Vietnam	-0.03 [-0.28, 0.22]
Kruger 1996a	South Africa	-0.02 [-0.32, 0.28]
Carmona-Fonseca 2015b	Colombia	0.01 [-0.15, 0.17]
Carmona-Fonseca 2015a	Colombia	0.13 [-0.05, 0.31]
Kirwan 2010	Nigeria	0.17 [-0.07, 0.41]
Dossa 2001b	Benin	0.20 [-0.45, 0.85]
Kruger 1996b	South Africa	0.27 [0.02, 0.52]
Ostwald 1984	Papua New Guinea	0.30 [-0.24, 0.84]
Dossa 2001a	Benin	0.30 [-0.29, 0.89]
MDA trials (prevalence >20%)		0.06 [-0.01, 0.14]
P-value = 0.098		
All MDA trials		0.03 [-0.03, 0.08]
P-value = 0.342		
I <sup>2</sup> = 0%		
Effects on infected children (all MDA trials)		0.11 [-0.04, 0.25]
P-value = 0.147		
<b>Panel C: Test-and-treat trials</b>		
Yap 2014 (I)	Myanmar, China	-0.40 [-1.25, 0.45]
Test-and-treat trials		-0.40 [-1.25, 0.45]
P-value = 0.356		
Effects on infected children (MDA and test-and-treat trials)		0.09 [-0.05, 0.24]
P-value = 0.203		